Standardized ketamine infusion protocol for chronic refractory pain: a retrospective study of preliminary effectiveness and treatment completion
Chronic refractory pain presents limited treatment options and diminished quality of life. While ketamine treatment shows promise, protocol variations and safety concerns have hindered widespread adoption. This study evaluated preliminary effectiveness and rate of treatment completion for a standard...
Uložené v:
| Vydané v: | Regional anesthesia and pain medicine |
|---|---|
| Hlavní autori: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
England
05.10.2025
|
| Predmet: | |
| ISSN: | 1532-8651, 1532-8651 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Chronic refractory pain presents limited treatment options and diminished quality of life. While ketamine treatment shows promise, protocol variations and safety concerns have hindered widespread adoption. This study evaluated preliminary effectiveness and rate of treatment completion for a standardized low-dose ketamine infusion therapy (KIT) protocol.
This retrospective observational study examined adult patients with chronic refractory pain who received KIT between May 2021 and October 2024 at the Cleveland Clinic's outpatient multidisciplinary pain clinic. Patients received a standardized protocol of 0.5 mg/kg ketamine infused over 40 min for five consecutive days. We measured effectiveness using patient-reported outcomes (PROs) at baseline, last infusion, and 3-month and 6-month post-treatment, and rate of treatment completion. The primary outcome of interest was the proportion of patients achieving clinically meaningful improvement on validated measures.
Among 1034 patients (mean age 50.4±15.2 years; 71.8% female; 83.3% of white ethnicity), treatment completion was high, with 890 (86.1%) patients completing 5+ infusions. No adverse events were reported. Baseline measures reflected moderate impairment in pain interference, global physical health, fatigue, physical function, and depression. Between 20.3% and 46.4% of patients achieved clinically meaningful improvement on PROs from baseline to last infusion, with similar proportions maintained at 3-month and 6-month follow-up. Statistically significant mean improvements were observed across multiple domains; however, the majority of individual outcomes did not reach clinically meaningful thresholds. Patients demonstrated significant mean improvements in fatigue, pain interference, and social role satisfaction (mean change -2.1±7.7, -2.0±5.8, and 2.0±7.7, respectively), with improvements in depression, social role satisfaction, pain interference, self-efficacy, global health, and pain catastrophizing sustained through 6 months post-treatment.
This standardized low-dose ketamine protocol demonstrated therapeutic benefit and high completion rates within a multidisciplinary care model. Future randomized controlled trials are warranted to confirm findings and explore treatment response factors across pain conditions. |
|---|---|
| AbstractList | Chronic refractory pain presents limited treatment options and diminished quality of life. While ketamine treatment shows promise, protocol variations and safety concerns have hindered widespread adoption. This study evaluated preliminary effectiveness and rate of treatment completion for a standardized low-dose ketamine infusion therapy (KIT) protocol.BACKGROUNDChronic refractory pain presents limited treatment options and diminished quality of life. While ketamine treatment shows promise, protocol variations and safety concerns have hindered widespread adoption. This study evaluated preliminary effectiveness and rate of treatment completion for a standardized low-dose ketamine infusion therapy (KIT) protocol.This retrospective observational study examined adult patients with chronic refractory pain who received KIT between May 2021 and October 2024 at the Cleveland Clinic's outpatient multidisciplinary pain clinic. Patients received a standardized protocol of 0.5 mg/kg ketamine infused over 40 min for five consecutive days. We measured effectiveness using patient-reported outcomes (PROs) at baseline, last infusion, and 3-month and 6-month post-treatment, and rate of treatment completion. The primary outcome of interest was the proportion of patients achieving clinically meaningful improvement on validated measures.METHODSThis retrospective observational study examined adult patients with chronic refractory pain who received KIT between May 2021 and October 2024 at the Cleveland Clinic's outpatient multidisciplinary pain clinic. Patients received a standardized protocol of 0.5 mg/kg ketamine infused over 40 min for five consecutive days. We measured effectiveness using patient-reported outcomes (PROs) at baseline, last infusion, and 3-month and 6-month post-treatment, and rate of treatment completion. The primary outcome of interest was the proportion of patients achieving clinically meaningful improvement on validated measures.Among 1034 patients (mean age 50.4±15.2 years; 71.8% female; 83.3% of white ethnicity), treatment completion was high, with 890 (86.1%) patients completing 5+ infusions. No adverse events were reported. Baseline measures reflected moderate impairment in pain interference, global physical health, fatigue, physical function, and depression. Between 20.3% and 46.4% of patients achieved clinically meaningful improvement on PROs from baseline to last infusion, with similar proportions maintained at 3-month and 6-month follow-up. Statistically significant mean improvements were observed across multiple domains; however, the majority of individual outcomes did not reach clinically meaningful thresholds. Patients demonstrated significant mean improvements in fatigue, pain interference, and social role satisfaction (mean change -2.1±7.7, -2.0±5.8, and 2.0±7.7, respectively), with improvements in depression, social role satisfaction, pain interference, self-efficacy, global health, and pain catastrophizing sustained through 6 months post-treatment.RESULTSAmong 1034 patients (mean age 50.4±15.2 years; 71.8% female; 83.3% of white ethnicity), treatment completion was high, with 890 (86.1%) patients completing 5+ infusions. No adverse events were reported. Baseline measures reflected moderate impairment in pain interference, global physical health, fatigue, physical function, and depression. Between 20.3% and 46.4% of patients achieved clinically meaningful improvement on PROs from baseline to last infusion, with similar proportions maintained at 3-month and 6-month follow-up. Statistically significant mean improvements were observed across multiple domains; however, the majority of individual outcomes did not reach clinically meaningful thresholds. Patients demonstrated significant mean improvements in fatigue, pain interference, and social role satisfaction (mean change -2.1±7.7, -2.0±5.8, and 2.0±7.7, respectively), with improvements in depression, social role satisfaction, pain interference, self-efficacy, global health, and pain catastrophizing sustained through 6 months post-treatment.This standardized low-dose ketamine protocol demonstrated therapeutic benefit and high completion rates within a multidisciplinary care model. Future randomized controlled trials are warranted to confirm findings and explore treatment response factors across pain conditions.DISCUSSIONThis standardized low-dose ketamine protocol demonstrated therapeutic benefit and high completion rates within a multidisciplinary care model. Future randomized controlled trials are warranted to confirm findings and explore treatment response factors across pain conditions. Chronic refractory pain presents limited treatment options and diminished quality of life. While ketamine treatment shows promise, protocol variations and safety concerns have hindered widespread adoption. This study evaluated preliminary effectiveness and rate of treatment completion for a standardized low-dose ketamine infusion therapy (KIT) protocol. This retrospective observational study examined adult patients with chronic refractory pain who received KIT between May 2021 and October 2024 at the Cleveland Clinic's outpatient multidisciplinary pain clinic. Patients received a standardized protocol of 0.5 mg/kg ketamine infused over 40 min for five consecutive days. We measured effectiveness using patient-reported outcomes (PROs) at baseline, last infusion, and 3-month and 6-month post-treatment, and rate of treatment completion. The primary outcome of interest was the proportion of patients achieving clinically meaningful improvement on validated measures. Among 1034 patients (mean age 50.4±15.2 years; 71.8% female; 83.3% of white ethnicity), treatment completion was high, with 890 (86.1%) patients completing 5+ infusions. No adverse events were reported. Baseline measures reflected moderate impairment in pain interference, global physical health, fatigue, physical function, and depression. Between 20.3% and 46.4% of patients achieved clinically meaningful improvement on PROs from baseline to last infusion, with similar proportions maintained at 3-month and 6-month follow-up. Statistically significant mean improvements were observed across multiple domains; however, the majority of individual outcomes did not reach clinically meaningful thresholds. Patients demonstrated significant mean improvements in fatigue, pain interference, and social role satisfaction (mean change -2.1±7.7, -2.0±5.8, and 2.0±7.7, respectively), with improvements in depression, social role satisfaction, pain interference, self-efficacy, global health, and pain catastrophizing sustained through 6 months post-treatment. This standardized low-dose ketamine protocol demonstrated therapeutic benefit and high completion rates within a multidisciplinary care model. Future randomized controlled trials are warranted to confirm findings and explore treatment response factors across pain conditions. |
| Author | Tankha, Hallie Kennemer, Austin Xu, Jijun Li, Yadi Gopalakrishnan, Raghavan Davin, Sara Schuster, Andrew Tankha, Pavan Lapin, Brittany |
| Author_xml | – sequence: 1 givenname: Hallie orcidid: 0000-0003-3210-7593 surname: Tankha fullname: Tankha, Hallie email: tankhah@ccf.org organization: Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA – sequence: 2 givenname: Sara surname: Davin fullname: Davin, Sara organization: Neurological Institute, Center for Spine Health, Cleveland Clinic, Cleveland, Ohio, USA – sequence: 3 givenname: Brittany surname: Lapin fullname: Lapin, Brittany organization: Neurological Institute Center for Outcomes Research & Evaluation, Cleveland Clinic, Cleveland, Ohio, USA – sequence: 4 givenname: Yadi surname: Li fullname: Li, Yadi organization: Neurological Institute Center for Outcomes Research & Evaluation, Cleveland Clinic, Cleveland, Ohio, USA – sequence: 5 givenname: Austin surname: Kennemer fullname: Kennemer, Austin organization: Case Western Reserve University School of Medicine, Cleveland, Ohio, USA – sequence: 6 givenname: Andrew surname: Schuster fullname: Schuster, Andrew organization: Neurological Institute Center for Outcomes Research & Evaluation, Cleveland Clinic, Cleveland, Ohio, USA – sequence: 7 givenname: Jijun orcidid: 0000-0002-5137-8199 surname: Xu fullname: Xu, Jijun organization: Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA – sequence: 8 givenname: Raghavan surname: Gopalakrishnan fullname: Gopalakrishnan, Raghavan organization: Center for Neurological Restoration, Cleveland Clinic, Cleveland, Ohio, USA – sequence: 9 givenname: Pavan surname: Tankha fullname: Tankha, Pavan organization: Neurological Institute, Center for Spine Health, Cleveland Clinic, Cleveland, Ohio, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/41047247$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkE9LxDAQxYOsuO7q3ZPk6KWapGma9SaL_0DwoJ6XNJlgtE1qkgr6KfzIBnYFTzPMvHk_3izQzAcPCJ1Qck5pLS6iGoeKEdZUlIgVaffQIW1qVknR0Nm_fo4WKb0RQmTLxQGac0p4y3h7iH6esvJGReO-weB3yGpwHrDzdkoueDzGkIMOPbYhYv0ag3caR7BR6RziFx6V85dYlVGOIY2gs_sEnPJkvnCw5Rx6VxxVkYK127WHlHCh4hxB5QF8xjoMYw-5EI_QvlV9guNdXaKXm-vn9V318Hh7v756qLpa0FzJjhrBDV-xjgi-IszoklYbKSnIztStZUJLqGsu7QpULWlnmtZoAYoBY5wt0dnWtyT8mCDlzeCShr5XHsKUNjVr2obxphCW6HQnnboBzGaMbiiBNn9fZL9-u3sY |
| ContentType | Journal Article |
| Copyright | American Society of Regional Anesthesia & Pain Medicine 2025. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ Group. |
| Copyright_xml | – notice: American Society of Regional Anesthesia & Pain Medicine 2025. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ Group. |
| DBID | NPM 7X8 |
| DOI | 10.1136/rapm-2025-106907 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1532-8651 |
| ExternalDocumentID | 41047247 |
| Genre | Journal Article |
| GroupedDBID | --- --K .Z2 026 0R~ 123 1B1 29P 5RE 5VS 7RV AAHLL AARTV AAWTL ABBUW ABJNI ABXVJ ACDDN ACEWG ACGFO ACGFS ACGOD ACWDW ACWRI ACXNZ AE6 AENEX AERUA AGINI AHMBA AJYBZ ALMA_UNASSIGNED_HOLDINGS BENPR BQLVK CS3 CXRWF DU5 E.X EX3 F5P FDB FL- HAJ HCIFZ HZ~ IHE IN~ JK8 KD2 L-C N9A NAPCQ NPM NQ- NXWIF O9- OHYEH OVD OXXIT P2P RMJ RPZ RWL S4S SDG SDP SEW SJN TAE TEORI V2I W3M WOW 7X8 |
| ID | FETCH-LOGICAL-b361t-8b1d64d492b064902dc153cd881e8bd37f26c8e3348f9ea381bd57dc6ea2e2242 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001587251900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1532-8651 |
| IngestDate | Tue Oct 07 08:26:59 EDT 2025 Tue Oct 07 09:50:13 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Fibromyalgia CHRONIC PAIN Complex Regional Pain Syndromes CLINICAL PAIN Pain Measurement |
| Language | English |
| License | American Society of Regional Anesthesia & Pain Medicine 2025. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ Group. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b361t-8b1d64d492b064902dc153cd881e8bd37f26c8e3348f9ea381bd57dc6ea2e2242 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-3210-7593 0000-0002-5137-8199 |
| OpenAccessLink | https://rapm.bmj.com/content/rapm/early/2025/10/05/rapm-2025-106907.full.pdf |
| PMID | 41047247 |
| PQID | 3257524549 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3257524549 pubmed_primary_41047247 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-10-05 |
| PublicationDateYYYYMMDD | 2025-10-05 |
| PublicationDate_xml | – month: 10 year: 2025 text: 2025-10-05 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Regional anesthesia and pain medicine |
| PublicationTitleAlternate | Reg Anesth Pain Med |
| PublicationYear | 2025 |
| SSID | ssj0008746 |
| Score | 2.4498765 |
| SecondaryResourceType | online_first |
| Snippet | Chronic refractory pain presents limited treatment options and diminished quality of life. While ketamine treatment shows promise, protocol variations and... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| Title | Standardized ketamine infusion protocol for chronic refractory pain: a retrospective study of preliminary effectiveness and treatment completion |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/41047247 https://www.proquest.com/docview/3257524549 |
| WOSCitedRecordID | wos001587251900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwGA3qRHzxfpk3IvgaXHNpUl9ExOGDGwMV9jbSXGCo7dymoL_Cn-yXNnNPguBLKaGhJT1JTr7L-RA6MxI2vRbVxHjpCRdGEJVpR4TPM8lY7qyoEoXvZLer-v2sFw1ukxhWOVsTq4XalibYyM8ZYEtQDseZy9ErCVWjgnc1ltBYRA0GVCagWvbnauFK1tlFgsGsT0Uyc1Oy9HysRy-AEBpkOMMB8XeCWW007fX_fuIGWosUE1_VmNhEC67YQiud6ETfRl_30Xww_HQWP7mpfoF2DFB7C6YzHKQbSsAHBj6LTS2ei2EjHVeleT7wSA-LC6yhaTouZ5mauNKpxaWH7u65KhUGj9bRInFBxfBW_BPYjqtgdhdwsYMe2zcP17ckFmYgOUuTKVF5YlNueUZzYDRZi1oDY2ysUolTuWXS09QoF5J8feY0kILcCmlN6jR1wBnoLloqysLtI8wT2jIJly74Q-FGe64BP8EhpFie-iY6nY31AIAfvBm6cOXbZDAf7Sbaq3_YYFQrdAx4EKCgXB78ofchWo04IC1xhBoepr07RsvmfTqcjE8qRMG12-t8A_by2iM |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Standardized+ketamine+infusion+protocol+for+chronic+refractory+pain%3A+a+retrospective+study+of+preliminary+effectiveness+and+treatment+completion&rft.jtitle=Regional+anesthesia+and+pain+medicine&rft.au=Tankha%2C+Hallie&rft.au=Davin%2C+Sara&rft.au=Lapin%2C+Brittany&rft.au=Li%2C+Yadi&rft.date=2025-10-05&rft.issn=1532-8651&rft.eissn=1532-8651&rft_id=info:doi/10.1136%2Frapm-2025-106907&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1532-8651&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1532-8651&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1532-8651&client=summon |